Cyteir Therapeutics
14 articles with Cyteir Therapeutics
-
Money on the Move: June 16 – 22
6/23/2021
Life sciences advances continue to be an exciting opportunity for investors. Here's a glance at the companies attracting fresh funding the past week. -
Cyteir Therapeutics Announces Closing of Initial Public Offering
6/22/2021
Cyteir Therapeutics, Inc. today announced the closing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share.
-
Cyteir Therapeutics Announces Pricing of Initial Public Offering
6/17/2021
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share
-
The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.
-
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program
2/11/2021
Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an oversubscribed $80 million Series C financing.
-
Cyteir Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/7/2021
Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies to treat cancer, today announced that Markus Renschler , M.D., Cyteir's president and chief executive officer, will present a scientific and business update at the 39th Annual J.P. Morgan Healthcare Conference on Monday,
-
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team
7/7/2020
- Phase 1/2 study of first-in-class inhibitor of RAD51-mediated homologous recombination advancing to once-daily dosing - Secrist, Gengos and Englert join Cyteir leadership team, enhancing company's scientific, strategic business development, and drug development expertise
-
Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
10/15/2019
Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an additional $40.2 million in the company's Series B financing, for a total of $75.2 million in this financing
-
Cyteir Therapeutics snagged $29 million and a new chief executive officer as the company pushes forward to develop small-molecule inhibitors in the fight against cancer.
-
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases
3/8/2018
Financing proceeds will be used to advance RAD51 inhibitor toward the clinic and expand small-molecule synthetic lethality platform for oncology and autoimmune diseases.
-
Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice From Type 1 Diabetes (T1D)
6/1/2017
-
Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID As A Novel Target For Cancer Treatment At AACR Annual Meeting
3/28/2017
-
Cyteir Therapeutics Presents Preclinical Data On Use Of DNA Repair Modulators For Lymphoid Malignancies At American Society of Hematology Annual Meeting
11/29/2016
-
Cyteir Therapeutics Receives $2 Million Grant From National Cancer Institute
6/29/2016